Marijuana Sector News

2 2836

Tokers are thanking the D.C. Council responsible for approving a measure this week that would make it against the law for employers in D.C. to test job seekers for pot before a job offer is made.

Lawmakers in the District thought it was time to make some progress on the bill called the “Prohibition of Pre-Employment Marijuana Testing Emergency Act of 2014,” which was introduced in March by Council Member Vincent Orange.

Basically, the bill would not allow employers to subject those applying for jobs to a pot test before a job offer was made. After someone is hired, then drug tests would be allowed, if that is what company policy states.

That doesn’t mean tokers are free to be stoned at work or even to continue their high habits. But it does give people some sense of security, knowing they can find a job even with some THC in their system.

“The citizens of the District voted for Initiative 71, to legalize marijuana, and this bill will protect citizens who legally smoke marijuana but are then subsequently penalized for it through loss of employment opportunities,” Orange said in a press release. “The bill aims to prevent the loss of a job opportunity for job seekers who have used marijuana prior to receiving a job offer but it does not remove an employer’s right to prohibit the use of drugs at work or at any time during employment.”

 

1 2558

Since the legalization of recreational marijuana retail shops have had more green than they know what to do with. There are warehouses full of cash all over the state. Banks are too afraid of the ramifications from the federal government if they provide banking services to these LEGAL businesses.

Things are looking up for dispensaries and retail stores in the Mile High state however. A marijuana banking co-op has gotten its charter from the state and is hoping to open its doors in early 2015.

The Fourth Corner Credit Union still has a lot of hoops to jump through before they are fully operational. One of the biggest things to still happen is to get approval and insurance from the National Credit Union Administration. The credit union is getting the green light at the state level though, with the backing of Governor Hickenlooper as a notable success for the co-op.

The issue for banks and legal pot businesses across the country comes from the fact that marijuana is illegal according to the feds and in order for a bank to do business they need to be insured by the federal government. This conundrum forces pot shops to store ridiculous amounts of cash, pay all their bills in cash, including payroll and they can’t offer credit card services to their customers. Not to mention the bookkeeping headache is causes. Storing large amounts of cash means dispensaries need to pay for beefed up security to protect all their green.

“I’m a pro state’s rights guy, and in Colorado we have legalized,” said Chris Myklebust, the Colorado commissioner of financial services. “When I pull a $20 bill out of my pocket, and look at the front, it says it’s legal tender for all debts public and private. Legal businesses in a state should be able to use the currency of the nation.”

The cash flow for pot stores and other green businesses in Colorado is huge. Federal investigators received a tip from a confidential informant that one particular Denver marijuana store was bringing in $500,00 a month, but tax records from the store showed it had taken $1.4 million for the entire year in question (2011).

This isn’t the only attempt to find a solution to the banking nightmare in Colorado since 2011. Most recently, at the of the May legislative session, a complicated bill was passed. The bill in the words of Rep. Jonathon Singer, “creates a financial-services cooperative for the marijuana industry that’s otherwise up until this point been unbanked. It gives businesses the opportunity to form a cooperative that works like a credit union, but with even more scrutiny — and no federal insurance.”

The Fourth Corner Credit Union isn’t related to the bill that passed. The Credit Union follows standard state credit union licensing, instead of needing approval by the federal government.

The Credit Union is hoping to open up for business January 1. Approval from the NCUA will likely still be pending at that time, but it they are allowed under state law to open for business with licenses still pending. Board Members for the Fourth Corner Credit Union are: Heather Jackson, of the Realm of Caring Foundation (the group behind Charlotte’s Web); Paige Figi, mother of the now-famous poster child for juvenile medical cannabis, Charlotte Figi (namesake for Charlotte’s Web); and Kristi Kelly, founder and CEO of Good Meds, other board members also include a real-estate broker, a disabled veteran and a PR agent.

0 3623

Even though medical marijuana is still not kosher with the federal government, that hasn’t stopped one drug (pharmaceutical) company from creating their own medical marijuana gum. They hope the chewing gum will have the approval of the FDA within a couple of years.

The company behind the ganja gum, is Axim Biotechnologies. They have offices in New York and the Netherlands. They have already produced a high-CBD gum, CanChew. The new THC gum they are now working on is called MedChew. It would be marketed to patients with Multiple Sclerosis, Irritable Bowel Disease and Crohn’s Disease.

Cannabis gum isn’t a new idea, but Axim is adamant that their product will stand out because of the time-released nature of their product. Their product has been developed so that the distribution of cannabinoids into the gastrointestinal tract takes place over a period of thirty minutes or so, which is a similar process to that of nicotine gum.

Axim also has their own team of growers who are in charge of growing all marijuana used in the making of their cannabis gum. The company has over an acre of land in the Netherlands which will be the new site of a grow setup in the near future.

“We get the raw materials from Bedrocan (a marijuana grow facility overseen by the Dutch Ministry of Health) as they have a GMP agricultural facility so the quality is highly qualified to make pharma products,” said Axim CEO, Lekhram Changoer.

MedChew is hoped to be launched in 2017, which would be just after the top medical marijuana pharma company GW Pharmaceuticals is expected to debut their cannabis products in the US.

0 5522

Written by Anthony DelCioppo

@spacenectar

Over the last few years a number of studies have shown that certain compounds found in cannabis have had success killing certain cancer cells and reducing growth in others. A new study has been published in the journal of Molecular Cancer Therapies showing that alongside radiation treatment, cannabis can help dramatically reduce one of the most aggressive types of brain tumors in mice.

A team of researchers from St. George’s University of London found that high-grade glioma masses (a deadly form of brain cancer) were reduced to as low as one tenth the original size when compared to the other tumors in the control group. Dr. Wai Liu, one of the study’s leading authors said, “We’ve shown that cannabinoids could play a role in treating one of the most aggressive cancers in adults. The results are promising…it could provide a way of breaking through glioma and saving more lives.”

What are Cannabinoids? Scientists have identified 85 known cannabinoids in the cannabis plant. The two most recognized are tetrahydrocannabinol (THC) and cannabidiol (CBD), both of which have their benefits when it comes to treating a number of diseases, including cancer.

THC is commonly known as the psychoactive component in cannabis that gets you high. But THC is also good for pain relief, muscle spasms, stimulating appetite, sleeping disorders, and nausea. In fact, Earlier this year Louisiana State University published a study in AIDS Research and Human Retroviruses, which suggested that THC can even stop the spread of HIV.

CBD on the other hand has proven successful in treating epilepsy, anxiety, pain, MS, schizophrenia, and PTSD. The CBD compound is used to treat patients for a variety of illnesses without the psychoactive side-effects like anxiety or paranoia attributed to THC.

The researchers from St. George’s University of London found that CBD and THC are both effective in fighting glioma, and concluded the tumors were best treated with low doses of both THC and CBD, as the tumors were more receptive to radiation treatment. Dr. Wai Liu told the Huffington Post, “Our data suggests a ‘triple threat’ approach using all three may be of value.”

But how exactly do CBD and THC kill cancer cells?

Humans have something called an Endocannabinoid System (ECS) which exists to receive cannabinoids that we naturally produce in the body. There are receptors for these cannabinoids in the brain, in our nervous system, and in cells associated with our immune system. CBD and THC can actually bind with our body’s cannabinoid receptors and essentially tell the cancer cells to ‘commit suicide.’

cbd2

Dr. Prakash Nagarkatti, a professor of Pathology and Microbiology at the University of South Carolina, conducted a similar study in 2011. He created a synthesized cannabis drug that was able to eradicate nearly 100% of the cancer in the test tubes. He then tested the same drug on mice and nearly 30% of the mice completely rejected the tumor, and the rest of the subjects showed significant reductions in size. Dr. Nagarkatti has begun clinical trials on patients with leukemia.

According to the American Cancer Society, in 2014 there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. With the information we already have and more research on the horizon, it would be irresponsible to continue to gloss over the fact that cannabis has shown remarkable effectiveness in treating cancer. But cannabis remains classified as a Schedule I drug and the federal government maintains that it has no medicinal value, despite all evidence to the contrary.

If there’s a silver lining though, it’s that 23 states and Washington D.C. disagree, paradoxical as it seems. And then there’s hemp. CBD can also be extracted from cannabis’ sister plant, hemp, which can be legally imported and sold in the US. With more cancer patients having access to the benefits of CBD and THC many of them are incorporating a more holistic approach and are seeing positive results. And not to go too far down the rabbit hole but it does beg the question, why is this medicine not federally legal?

At the very least it should be treated like any other prescription drug that your doctor would write you a script for, much like they do in Canada, eh? Obviously there are many reasons and it’s extremely complex, but for the sake of addressing my question let’s simplify it: follow the money. According to the National Cancer Institute, medical costs for cancer care are $125 billion and are expected to jump to $173 billion in the next 5 years.

And while the marijuana industry is no slouch with a $35 billion projected value by 2020 (assuming all states and the federal government go legal), it’s a drop in the bucket relative to cancer care.

Carter Pewterschmidt and Brian from Family Guy paint the picture:


Brian: “Carter, you’ve discovered the holy grail of modern medicine. Why the hell would you keep it buried like this?”

Carter: “I’ll tell you why, because there’s far more money to be made treating a disease than in curing it. Why cure someone of cancer in a day when we can treat them for a life time and bill them every step along the way?”

Brian: “What? That’s insane!”

Touché, Brian.

2 4376

Medical marijuana patients in the state of Minnesota are one step closer to being able to access marijuana….in limited forms. The State Department of Health announced on Monday that they have chosen the two entities that will be the sole providers of medical cannabis for the state’s medical program.

The state medical program is limiting cannabis to concentrates and edibles. The two providers that were chosen will be responsible for making the products. No raw cannabis will be allowed in the program.

The two providers chosen are Leafline Labs and Minnesota Medical Solutions. Leafline will have it’s home base in Cottage Grove, Minnesota and there will be a dispensary in Eagan, hopefully opening in July 2015. Leafline also plans to open dispensaries in St. Paul, St. Cloud and Hibbing down the road. Minnesota Medical Solutions will be based on Ostego and will have dispensaries in Minneapolis, Maple Grove and Moorehead.

There were ten other providers who also applied to be a part of the states program.

There has been a lot of criticism of the state’s medical program. Activists in the state think the program is too restrictive and doesn’t allow for people with severe pain to access the program. Doctors in the state are also required to be part of an ongoing study which will determine if medical marijuana works or not.

1 2688

Since the legalization of recreational marijuana retail shops have had more green than they know what to do with. There are warehouses full of cash all over the state. Banks are too afraid of the ramifications from the federal government if they provide banking services to these LEGAL businesses.

Things are looking up for dispensaries and retail stores in the Mile High state however. A marijuana banking co-op has gotten its charter from the state and is hoping to open its doors in early 2015.

The Fourth Corner Credit Union still has a lot of hoops to jump through before they are fully operational. One of the biggest things to still happen is to get approval and insurance from the National Credit Union Administration. The credit union is getting the green light at the state level though, with the backing of Governor Hickenlooper as a notable success for the co-op.

The issue for banks and legal pot businesses across the country comes from the fact that marijuana is illegal according to the feds and in order for a bank to do business they need to be insured by the federal government. This conundrum forces pot shops to store ridiculous amounts of cash, pay all their bills in cash, including payroll and they can’t offer credit card services to their customers. Not to mention the bookkeeping headache is causes. Storing large amounts of cash means dispensaries need to pay for beefed up security to protect all their green.

This isn’t the only attempt to find a solution to the banking nightmare in Colorado since 2011. Most recently, at the of the May legislative session, a complicated bill was passed. The bill in the words of Rep. Jonathon Singer, “creates a financial-services cooperative for the marijuana industry that’s otherwise up until this point been unbanked. It gives businesses the opportunity to form a cooperative that works like a credit union, but with even more scrutiny — and no federal insurance.”

The Fourth Corner Credit Union isn’t related to the bill that passed. The Credit Union follows standard state credit union licensing, instead of needing approval by the federal government.

The Credit Union is hoping to open up for business January 1. Approval from the NCUA will likely still be pending at that time, but it they are allowed under state law to open for business with licenses still pending. Board Members for the Fourth Corner Credit Union are: Heather Jackson, of the Realm of Caring Foundation (the group behind Charlotte’s Web); Paige Figi, mother of the now-famous poster child for juvenile medical cannabis, Charlotte Figi (namesake for Charlotte’s Web); and Kristi Kelly, founder and CEO of Good Meds, other board members also include a real-estate broker, a disabled veteran and a PR agent.

0 1620

Plandai Biotechnology, Inc. Highlighted in Newly Published Article by South Africa’s Department of Science & Technology

SEATTLE, WA–(Marketwired – December 01, 2014) – Plandaí Biotechnology, Inc. (PLPL(“Plandaí” or “the Company”), a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that the Company has been highlighted in an article titled “‘Secret’ Technology Turns Local Farm into Green Tea Extract Factory” in the December edition of the Republic of South Africa’s Department of Science & Technology: Public Understanding of Biotechnology Newsletter. The article, which was reviewed by independent experts through the South African Agency for Science and Technology Advancement (SAASTA) Scientific Editorial Process, can be found at: http://www.pub.ac.za/newsletter/02-201412/article-1.html.

The Department of Science and Technology launched a Public Understanding of Biotechnology (PUB) program to ensure a clear, balanced understanding of the scientific principles, related issues and potential of biotechnology and to stimulate public debate around its applications in society. In its monthly newsletter, the Department covers a variety of topics and issues that help to further educate the public in biotechnology.

December’s PUB newsletter offers a full feature article that looks into Plandaí’s efforts to bring the once abandoned Senteeko Tea Estate back to life, the growing and harvesting process of the Company’s green tea and other plants, the “secret” technology employed at Plandaí, an interview with the Company’s President and CEO, Roger Duffield, the work to bring higher bioavailability extracts to market, and much more.

In an excerpt from the article, the author writes, “That farm was abandoned.” Duffield recalls. “The tea bushes were 20 feet high, the roads didn’t exist and the old tea factory had been ransacked with the roofs caved in and owls nesting in it.”

A few years…later, the Senteeko estate in the Barberton District of Mpumalanga is now a lush and neatly-maintained tea farm hidden deep within hundreds of hectares of Sappi paper plantations, with Plandaí’s brand new, on-site agro-processing facility soon to ship its first batch of Phytofare™ Catechin Complex from green tea.

Access the article at: http://www.pub.ac.za/newsletter/02-201412/article-1.html.

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company’s products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí’s ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Contact:
Andrew Beyer
Phone: 888-627-6902
Email: investor@Plandaíbiotech.com

0 1475

Easton Pharmaceuticals Finalizes and Forwards Its 2013 Audited Financials to an Existing Medical Marihuana Acquisition Target and a Health Canada Medical Marijuana for Medical Purposes (MMPR) Applicant

TORONTO, ON–(Marketwired – Dec 1, 2014) – Easton Pharmaceuticals Inc. (OTC: EAPH) announces it has arranged to have its completed 2013 audit to be handed over to two American and Canadian based Medical Marihuana Growers whom the company has had ongoing communications with. As previously stated, grower details are expected to be disclosed within the second week of December as per allowances made on due diligence documentation and agreements.

Easton has been considering entering the lucrative Medical Marijuana industry mainly through the acquisition route. Current acquisition candidates have insisted on an independent audit on its 2013 year end financial statements prior to considering and accepting restricted shares of Easton Pharmaceuticals common stock as part of its ongoing negotiations. Current auditor has been vetted by the candidates to ensure that standards would be acceptable to all parties.

In other developments involving Easton’s current Canadian medical marijuana facility / initiative, the applicants have undergone communications with Health Canada and are hoping to be one of the next few company’s processed by health Canada. There have been expectations that Health Canada would review, inspect and finalize applications by end of year and start approving applicants early into the new year (2015). Easton Pharmaceuticals has received a full financing commitment through an accredited private Canadian investor, contingent on receiving an MMPR license. In addition a second investor option from a New York based accredited investor have provided Easton with a commitment for up to $5,000,000 in financing who have previously financed the company in the amount of $1,000,000 .

Easton Pharmaceuticals is striving to become not just another player in the industry but a potent company that will deliver a great value proposition to its shareholders and partners.

About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs and therapeutic / cosmetic healthcare products focused on cancer and other health issues geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions that are all in various stages of development. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 50% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com

Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when used in the preceding of discussion, the words “hope”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

Contact:
Carla Pepe
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email:
info@eastonpharmaceuticalsinc.com

2 10020

There are very few people in the world that fall in the WW[BLANK]D category besides probably the big man himself. (Not Talking about Jesus Christ)

BUT investors around the world often find themselves asking ‘What Would Warren Buffett Do?’ just before or after making an investment.  Is it the right move for me? Will it make money? Should I take my profit or loss now?  All great questions but in the end I would say that it all comes back to the Oracle of Omaha himself.  So with that, What Would Warren Buffett Do in the case of an investment in marijuana stocks?

 

 

Big Buff’s Strategy 

To really grasp this to its fullest you really need to strip it down to the bare bones of Buffett’s investment fundamentals.  Warren Buffett is one of the richest men in the world. He built his fortune using a simple yet powerful investment strategy. His investments are long-term positions, accomplished by the purchase of strong companies that are trading well below their intrinsic value.  In a speech at Columbia Business School, later adapted into an essay, Buffett introduced what he called, “The Superinvestors of Graham-and-Doddsville.” (Benjamin Graham — whom Buffett studied under at Columbia — and Dave Dodd, with whom Graham wrote the book on security analysis…literally)

 

“The common intellectual theme of the investors from Graham-and-Doddsville is this: they search for discrepancies between the value of a business and the price of small pieces of that business in that market.”

 

In other words, Buffett doesn’t think about buying a stock; he thinks about buying a business. Buffett explains his thesis is based on the idea that the investors of Graham-and-Doddsville could care less about when they buy stocks, or be concerned about a stock’s beta or the “covariance in returns among securities.”

 

“These investors are businessmen buying pieces of businesses, not traders buying stocks.”

 

So when you think of it in a way of an acquisition based approach, the ideology of an investment versus the action of a trade takes a more profound meaning and with it, an entirely new sense of placing value on a stock and its underlying company.

Are Marijuana Stocks Warren’s ‘Pot’ of Gold?

 

Some would say that marijuana stocks could offer several key factors that Buffett looks for in the investments he makes.  For starters, Buffett relies on long-term trends and doesn’t necessarily concern himself with a bad quarter here or there. As long as business is growing and the product continues to “sell itself”, he is content (coming from a simplistic view of the WWWBD approach).  Banks, insurers, soft-drink makers, and railroads for example all benefit from a growing population that needs access to cash, ability to protect themselves from those unseen circumstances, and who can argue with Santa Claus pounding a glass bottle of Coke during the holidays?  When it comes to popular opinion, it would appear that as Americans, we’re all starting to look at weed the same way others look at Coca Cola…sure its loaded with sugar but “it’s not that bad.”

 

A recent Gallup poll conducted just prior to the midterm elections shows that “public support for legalizing the use of marijuana has clearly increased over the past decade.”  Furthermore “with a super-majority of younger Americans supportive — 64% of those aged 18 to 34, contrasted with 41% of those 55 and older — it seems inevitable that [legalization outside of more liberal states] will eventually change.”

 

Also in line with Buffett’s philosophy, price elasticity comes into play or rather the propensity for someone to buy a good regardless of price.  Marijuana could be seen as an inelastic commodity as so far it seems no matter what the price is, people are willing to buy.  Marijuana, in turn is something that at this point has a consistent demand unrelated to any other economic factors. Put another check mark in the “Buffett box”.

 

No Smoke, No Mirrors…Just Barriers

 

One thing that may not necessarily appeal to the Warren Buffett philosophy is the relatively easy road to getting involved in the marijuana industry.  Seemingly, it doesn’t appear that competition would be hot enough to have 4 or 5 major industry leaders to shake up the MJ space…just yet.

 

While rules and regulations definitely put up a wall when it comes to getting approved for a license (as a marijuana retailer), and patents would protect drugs developed by MJ companies focused on pharmaceutical applications, entering the marijuana industry isn’t all that hard…just look at the myriad companies already doing it in the penny stock market.

 

But here’s where the hook might be and it actually starts in the auto industry.  A recent article in Bloomberg Business Week cites that “In buying a chain of car dealerships, Buffett’s Berkshire Hathaway (BRK/B) sees plenty of moats (barriers to entry) and a clear path to consolidation.”

 

The industry is highly fragmented, for example the 10 largest U.S. dealers account for less than 10 percent of new vehicle sales (according to Morningstar). Buffett’s Berkshire Hathaway has plenty of opportunity to buy other dealers and help concentrate the industry This not only gives the company a cost advantage but by taking more of a “roll-up” approach, it gives pricing advantages as well.   Remember the reason why I said he might not like the industry?  Well it could be exactly why he should like it in the end.  In essence Buffett’s strategy would make him an industry leader that the market is currently lacking.

 

Could The Future Hold A Berkshire That Purports A Position in Pot?

Right now it’s probably not a likely avenue that this conglomerate would jump into.  We’re not even a year into the first legal recreational states reporting fiscal tax revenue nor is the country unanimously legalizing the drug.  It’s a very interesting scenario: You can go from Oregon to Washington with a joint and no one should seemingly care but the minute you cross into another state, you could potentially get put in jail for life!

WWWBD?  Probably stay far away from an investment where buyers of the product potentially face that kind of outcome.  So until the industry levels out, there is a clear track record of strong & consistent revenue, and until the industry is fully accepted in all states, I don’t foresee the ‘Oracle planning a portfolio strategy on marijuana stocks in the near future…but stranger things have happened so time will be the judge here in my opinion.

0 1609

NTRR CEO: ‘Historic’ Federal Hearing Could Be Beginning of the End of Cannabis Prohibition

TAMPA, Fla.–(BUSINESS WIRE)–

A federal hearing underway in California challenging cannabis’ Schedule I DEA classification could lead to the current nationwide ban being declared unconstitutional, which would expand the consumer base for companies like Neutra Corp. (NTRR) that offer ancillary products to the marketplace.

Last month, a U.S. district judge in Sacramento granted the three-day examination into cannabis’ Schedule I DEA classification, which has classified the herb as a dangerous, illegal drug for more than 40 years. Stanford law professor Robert MacCoun told The Christian Science Monitor, “If we were starting from scratch, I very much doubt we’d put marijuana in Schedule I. But now that it’s there, it isn’t easy to move out.” The hearing has been granted because the legal counsel for two men charged with cultivating cannabis submitted expert accounts showing new scientific and medical evidence they say proves that the herb does not fit the criteria of a Schedule I drug. If the court agrees, cannabis’ Schedule I status could be ruled unconstitutional.

Last week, the district court directed the prosecution and defense in U.S. vs. Schweder to file simultaneous briefs on the constitutionality of cannabis being classified as a Schedule I controlled substance by December 17.

“This is a historic case for the U.S. cannabis industry and could be the beginning of the end for prohibition if the judge rules to reclassify the herb. It could go either way and we know the legal standards are very high. We’re cautiously optimistic,” said NTRR CEO Chris Brown. “But no matter how the judge rules, there is overwhelming momentum building in this industry as demand for better, all-natural wellness solutions grows. Either way, we’re preparing to bring cultivation and delivery systems to the U.S. cannabis marketplace.”

NTRR is working to capitalize on the nationwide wave of cannabis decriminalization and legalization by offering new technologies to cannabis consumers and producers alike. The company is working with joint venture partners to deliver new vaporizer pens with groundbreaking versatility as well as portable, self-contained indoor growing environments treated with antimicrobial coatings.

About Neutra Corp.

Neutra Corp. is a healthy lifestyle company that specializes in the development and marketing of natural wellness solutions, including cannabis-related products. By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (GWPRF), Growlife Inc. (PHOT) and Medbox Inc. (MDBX), delivering technological advancements in the cultivation and processing of cannabis in approved markets. For investing information and performance data, please visit www.neutracorp.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact:
Neutra Corp.
Chris Brown, 813-367-2041
President and CEO
info@neutracorp.com

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements